APA (7th ed.) Citation

Beitzen-Heineke, A., Berenbrok, N., Waizenegger, J. S., Paesler, S., Gensch, V., Udonta, F., . . . Loges, S. (2021). AXL inhibition represents a novel therapeutic approach in BCR-ABL negative myeloproliferative neoplasms. HemaSphere, 5(9), .

Chicago Style (17th ed.) Citation

Beitzen-Heineke, Antonia, et al. "AXL Inhibition Represents a Novel Therapeutic Approach in BCR-ABL Negative Myeloproliferative Neoplasms." HemaSphere 5, no. 9 (2021).

MLA (9th ed.) Citation

Beitzen-Heineke, Antonia, et al. "AXL Inhibition Represents a Novel Therapeutic Approach in BCR-ABL Negative Myeloproliferative Neoplasms." HemaSphere, vol. 5, no. 9, 2021.